id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-258602-dnzqiq8k	Cortegiani, A.	Rationale and Evidence on the use of Tocilizumab in COVID-19: A Systematic Review	2020-07-20		.txt	text/plain	1850	95	45	METHODS: MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20(th) June 2020. The aim of this review was to describe the rationale and summarize the available evidence, direct and indirect, regarding the use of tocilizumab for treatment of SARS-CoV-2 infection and to identify and describe ongoing clinical trials with this drug. We sought pre-clinical and clinical studies addressing the use of tocilizumab for treating COVID-19, SARS-CoV-2 infection, viral pneumonia, and/or sepsis. In order to find prepublication manuscripts, we surveyed the pre-print repositories biorRxiv and medRxiv from inception to 20 th June 2020 for clinical or pre-clinical studies about the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis. Finally, to identify clinical trials studying treatment with tocilizumab for COVID-19, SARS-CoV-2 infection, viral pneumonia, and/or sepsis, we sought trials registered prior to 20 th June 2020 in the Chinese Clinical Trial Registry and Clinicatrial.gov.	./cache/cord-258602-dnzqiq8k.txt	./txt/cord-258602-dnzqiq8k.txt